|
| Exchange Received Time 11/08/2017 19:52:32 Exchange Disseminated Time 11/08/2017 19:52:38 Time Taken 00:00:06 | Update on acquisition of 203,135 Series A Preferred Stock of Krystal Biotech Inc., USA - completion of transaction
We refer to our disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, vide our letter dated August 8, 2017 regarding agreement to acquire 203,135 Series A Preferred Stock (equivalent to 15.91% fully diluted equity stake on conversion) of Krystal Biotech Inc., United States of America.
Further to the above, we wish to inform you that all the necessary formalities for completion of acquisition of 203,135 Series A Preferred Stock (equivalent to 15.91% fully diluted equity stake on conversion) of Krystal Biotech Inc., have now been concluded.
|
|
|